JP2013537891A5 - - Google Patents

Download PDF

Info

Publication number
JP2013537891A5
JP2013537891A5 JP2013528384A JP2013528384A JP2013537891A5 JP 2013537891 A5 JP2013537891 A5 JP 2013537891A5 JP 2013528384 A JP2013528384 A JP 2013528384A JP 2013528384 A JP2013528384 A JP 2013528384A JP 2013537891 A5 JP2013537891 A5 JP 2013537891A5
Authority
JP
Japan
Prior art keywords
patent document
composition
cyclodextrins
aspirin
drugs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013528384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013537891A (ja
JP5890951B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/051386 external-priority patent/WO2012037117A1/en
Publication of JP2013537891A publication Critical patent/JP2013537891A/ja
Publication of JP2013537891A5 publication Critical patent/JP2013537891A5/ja
Application granted granted Critical
Publication of JP5890951B2 publication Critical patent/JP5890951B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013528384A 2010-09-13 2011-09-13 不快味マスキング剤を有する水性薬物送達システム Expired - Fee Related JP5890951B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38209810P 2010-09-13 2010-09-13
US61/382,098 2010-09-13
PCT/US2011/051386 WO2012037117A1 (en) 2010-09-13 2011-09-13 Aqueous drug delivery system comprising off - flavor masking agent
US13/231,150 2011-09-13
US13/231,150 US9018193B2 (en) 2010-09-13 2011-09-13 Aqueous drug delivery system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016029886A Division JP6263699B2 (ja) 2010-09-13 2016-02-19 不快味マスキング剤を有する水性薬物送達システム

Publications (3)

Publication Number Publication Date
JP2013537891A JP2013537891A (ja) 2013-10-07
JP2013537891A5 true JP2013537891A5 (enExample) 2014-11-06
JP5890951B2 JP5890951B2 (ja) 2016-03-22

Family

ID=44674918

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013528384A Expired - Fee Related JP5890951B2 (ja) 2010-09-13 2011-09-13 不快味マスキング剤を有する水性薬物送達システム
JP2016029886A Expired - Fee Related JP6263699B2 (ja) 2010-09-13 2016-02-19 不快味マスキング剤を有する水性薬物送達システム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016029886A Expired - Fee Related JP6263699B2 (ja) 2010-09-13 2016-02-19 不快味マスキング剤を有する水性薬物送達システム

Country Status (15)

Country Link
US (4) US9018193B2 (enExample)
EP (2) EP2616046B1 (enExample)
JP (2) JP5890951B2 (enExample)
KR (1) KR20140007798A (enExample)
CN (1) CN103209684A (enExample)
AU (1) AU2011302293B2 (enExample)
BR (1) BR112013005987A2 (enExample)
CA (1) CA2811202A1 (enExample)
IL (1) IL225149B (enExample)
MY (1) MY162175A (enExample)
NZ (1) NZ608239A (enExample)
PH (1) PH12013500477A1 (enExample)
RU (1) RU2013116336A (enExample)
SG (2) SG10201507554RA (enExample)
WO (1) WO2012037117A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015175982A1 (en) * 2014-05-16 2015-11-19 Vivus, Inc. Orally administrable formulations for the controlled release of a pharmacologically active agent
US11623008B2 (en) * 2014-08-20 2023-04-11 Professional Compounding Centers Of America Excipient compositions for mucoadhesive pharmaceutical compositions including a synergistic combination of amylopectin, pullulan, hyaluronic acid, and xyloglucan
WO2016092547A1 (en) * 2014-12-09 2016-06-16 Ezekiel Golan Alcoholic beverage substitutes
WO2016092546A1 (en) 2014-12-09 2016-06-16 Ezekiel Golan Binge behavior regulators
US11345762B2 (en) * 2015-04-07 2022-05-31 Nissan Chemical Industries, Ltd. Method for preparing liquid medium composition, and preparation device and kit therefor
US10493083B2 (en) 2015-10-30 2019-12-03 Cmp Development Llc Spironolactone aqueous compositions
US20210290524A1 (en) * 2016-09-06 2021-09-23 Children's Medical Center Corporation Topical trpv1 antagonists and methods and compositions thereof
CN116869983A (zh) * 2016-09-16 2023-10-13 锡德克斯药物公司 包含对乙酰氨基酚和磺烷基醚环糊精的制剂
CN119970625A (zh) * 2018-01-15 2025-05-13 西雅图咖米公司 半固态抗组胺组合物及其制备和使用方法
US10828286B2 (en) * 2018-05-24 2020-11-10 Gm Pharmaceuticals, Inc. Niacin and berberine compositions and methods of use thereof
US12522670B2 (en) 2018-06-29 2026-01-13 Roquette Freres Hydroxypropyl-beta-cyclodextrin and process for the production thereof
JP2020019731A (ja) * 2018-07-31 2020-02-06 日本食品化工株式会社 アムロジピンベシル酸塩の苦味抑制剤
JP6711875B2 (ja) * 2018-08-29 2020-06-17 日本食品化工株式会社 マクロライド化合物の苦味抑制剤
CN112544970B (zh) * 2020-12-11 2022-11-04 江南大学 一种包埋脂溶性功能因子的淀粉基双乳液的制备方法
US11452690B1 (en) * 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
GR1010732B (el) * 2023-06-02 2024-07-25 Ιουλια Κλεωνος Τσετη Φαρμακευτικη συνθεση ιβουπροφαινης και παρακεταμολης για απο του στοματος χορηγηση
CN119185191A (zh) * 2024-09-12 2024-12-27 广东心宝药业科技有限公司 一种口服液药物口感的控制方法及系统

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
GB9226391D0 (en) 1992-12-18 1993-02-10 Cpc International Inc Xanthan gelling agents
US5362860A (en) 1993-02-01 1994-11-08 Warner-Lambert Company Neutral stabilization complex for CI-979 HCl, a cognition activator
FR2704146B1 (fr) 1993-04-19 1995-07-13 Cripdom Microcapsules d'acide acétylsalicylique à libération contrôlée.
US5651980A (en) 1994-04-15 1997-07-29 Biohybrid Technologies, Inc. Methods of use of uncoated gel particles
US6319535B1 (en) 1995-11-28 2001-11-20 Laurence J. Shaw Confections that “swim” in a carbonated beverage
ES2212085T3 (es) 1996-10-09 2004-07-16 Givaudan Sa Procedimiento para la preparacion de granulos como aditivo para alimentos.
JP2001508411A (ja) 1996-11-29 2001-06-26 モンサント・カンパニー 生物学的活性成分の経口投与のための潤滑性自立型（インタクト）ゲル
US5776431A (en) 1997-03-26 1998-07-07 Galat; Alexander Water-soluble aspirin composition
EP0974366B1 (en) 1997-03-28 2006-10-18 Eisai Co., Ltd. Oral pharmaceutical preparations decreased in bitterness by masking
BE1011251A3 (fr) 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
EP1009410B1 (de) 1997-07-15 2003-03-12 Walter Burghart Verfahren zum herstellen von stabilen acetylsalicylsäure-lösungen
WO1999022768A1 (en) 1997-10-31 1999-05-14 Monsanto Company Controlled release compositions comprising gellan gum gels
US6572898B2 (en) 1999-05-21 2003-06-03 Pts Labs Llc Electrolyte gels for maintaining hydration and rehydration
SK282717B6 (sk) 2000-03-10 2002-11-06 �Stav Experiment�Lnej Farmakol�Gie Sav Spôsob prípravy ultravysokomolekulových hyalurónanov
DE60130907T2 (de) 2000-10-16 2008-06-19 Pepsico Inc. Verfahren zur herstellung von mit calzium angereicherten getränken
US7141555B2 (en) 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
US7494669B2 (en) 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
EP1478404A1 (en) * 2002-02-22 2004-11-24 Pharmacia Corporation Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
US20090215735A1 (en) * 2002-02-25 2009-08-27 Alcon, Inc. Topical solution formulations containing a corticosteroid and a cyclodextrin
WO2003074086A1 (fr) 2002-03-04 2003-09-12 Medrx Co., Ltd. Matrice liquide a transfert de phase in vivo, et preparations liquides orales
AU2003246489A1 (en) 2002-07-19 2004-02-09 Vitalstate Canada Ltd. Oral delivery system containing a gel matrix and liposomes
US7713551B2 (en) 2002-09-11 2010-05-11 Elan Pharma International Ltd. Gel stabilized nanoparticulate active agent compositions
US20060018972A1 (en) 2002-11-26 2006-01-26 Upm Pharmaceuticals, Inc. Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
US7160565B2 (en) 2003-03-31 2007-01-09 Breakthru Products, Llc Hydration beverage and method of delivering nutrients
KR101059057B1 (ko) 2003-09-12 2011-08-24 류가쿠산 가부시키가이샤 쓴맛을 차단할 수 있는 과립상 젤리 음료
EP1674088A4 (en) 2003-10-17 2009-04-15 Medrx Co Ltd Grape-based preparation containing a biguaneid drug
IL160095A0 (en) 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs
CA2547934C (en) * 2004-02-19 2013-05-21 Abbott Laboratories Methods of using gamma cyclodextrin to control blood glucose and insulin secretion
US8383154B2 (en) 2004-05-11 2013-02-26 Egalet A/S Swellable dosage form comprising gellan gum
US20080044481A1 (en) 2004-05-27 2008-02-21 Mordechai Harel Microparticles for Oral Delivery
CA2574602A1 (en) 2004-07-22 2006-02-02 Pfizer Products Inc. Taste masking formulation comprising the drug in a dissolution-retarded form and/or cyclodextrin in a dissolution-enhanced form
US20070092561A1 (en) 2005-06-24 2007-04-26 Don Milne Water-Soluble Aspirin Composition
US8715731B2 (en) 2006-03-22 2014-05-06 Isp Investments Inc. Process of reducing the bitter taste of water soluble actives by co-grinding the active with β cyclodextrin
PT103476B (pt) 2006-05-10 2008-09-19 Univ De Coimbra Processo de produção e isolamento de micro- e nanopartículas poliméricas contendo macromoléculas de natureza hidrofílica e termolábil
MX2009000046A (es) 2006-07-06 2009-06-05 Abbott Respiratory Llc Hidrogeles superporosos para aplicaciones de alto rendimiento.
WO2008007383A1 (en) 2006-07-14 2008-01-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dried electrified hydrocolloid gels having unique structure and porosity
US20090304784A1 (en) 2006-07-28 2009-12-10 V. Mane Fils Seamless capsules containing high amounts of polyunsaturated fatty acids and a flavouring component
GB0616794D0 (en) * 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
JP5205909B2 (ja) * 2006-10-18 2013-06-05 大正製薬株式会社 粘膜適用液剤
JP5048398B2 (ja) * 2007-06-13 2012-10-17 大蔵製薬株式会社 抗真菌剤の医薬組成物
WO2009008006A2 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
KR100937625B1 (ko) 2007-08-10 2010-01-20 주식회사 제닉 가용성 웹 공극필름 및 이의 제조방법
US9186640B2 (en) 2007-08-28 2015-11-17 Pepsico, Inc. Delivery and controlled release of encapsulated lipophilic nutrients
EP2583669A1 (en) * 2007-10-10 2013-04-24 Rubicon Research Private Limited Taste-masked orally disintegrating tablets of memantine hydrochloride
AU2007360026B9 (en) 2007-10-12 2013-07-11 Ryukakusan Co. Ltd. Granular jelly beverage for medication and process for producing the same
US20090104251A1 (en) 2007-10-22 2009-04-23 Sensient Flavors Inc. Heat stable microcapsules and methods for making and using the same
US8563066B2 (en) * 2007-12-17 2013-10-22 New World Pharmaceuticals, Llc Sustained release of nutrients in vivo
BRPI0822111B8 (pt) 2007-12-20 2021-05-25 Nutricia Nv composição líquida, e, uso de uma composição líquida
ES2402753T3 (es) 2008-02-06 2013-05-08 University Of East Anglia Composición y método para ayudar a la deglución
WO2009132050A2 (en) 2008-04-21 2009-10-29 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
WO2009130704A1 (en) 2008-04-24 2009-10-29 Technion Research And Development Foundation Ltd. Beta-lactoglobulin-polysaccharide nanoparticles for hydrophobic bioactive compounds
GB0813929D0 (en) 2008-07-30 2008-09-03 Glaxo Group Ltd Novel method
US9414615B2 (en) * 2010-01-18 2016-08-16 PepciCo, Inc. Gel-based compositions and methods of making same

Similar Documents

Publication Publication Date Title
AU2024227357A1 (en) Ganaxolone For Use In Treating Genetic Epileptic Disorders
Saini et al. Motor and non-motor symptoms, drugs, and their mode of action in Parkinson’s disease (PD): a review
JP5589130B1 (ja) 結晶及び該結晶を含有してなる医薬製剤
JP2014528474A5 (enExample)
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
EA201290026A1 (ru) Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
JP6456533B2 (ja) ロキソプロフェン含有外用剤組成物
Lehrer-Graiwer et al. GBT440, a potent anti-sickling hemoglobin modifier reduces hemolysis, improves anemia and nearly eliminates sickle cells in peripheral blood of patients with sickle cell disease
JP2010515682A5 (enExample)
CN107951869A (zh) 含有大麻二酚的药物制剂及其应用
JP2013541583A (ja) 組み合わせ組成物
JP5842058B2 (ja) 自閉症の治療における使用のためのクレンブテロール
TW201034674A (en) Uses of NK receptor antagonists
KR20160118234A (ko) 만성 신장병의 진행 억제 또는 개선제
CN104013638B (zh) 当药黄素及其衍生物的用途
Brown et al. GBT021601, a next generation HbS polymerization inhibitor: results of safety, tolerability, pharmacokinetics and pharmacodynamics in adults living with sickle cell disease and healthy volunteers
CN115803040A (zh) 用于处理covid-19和相关病症的组合物
JP5815273B2 (ja) 抗炎症剤組成物
CN102716120B (zh) (3r)-去-o-甲基毛狄泼老素在制备预防或治疗抑郁症的药物中的用途
JP6454436B1 (ja) ペマフィブラートを含有する医薬
JP7312286B2 (ja) うつ病を予防または治療するための安息香酸またはその塩および誘導体
TW200831072A (en) Non-steroidal anti-inflammatory drugs for cough
JP6178058B2 (ja) 抗炎症及び／又は抗ヒスタミン剤組成物
CN117715633A (zh) 用于治疗covid-19、自身免疫性疾病或细胞因子风暴反应的利多卡因或阿替卡因
WO2014057180A1 (fr) Utilisation d'un melange argon/xenon pour prevenir ou traiter les consequences neurologiques d'un choc septique